1. Relapsed/Refractory Follicular Lymphoma Conundrums

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Epidemiology of FL

4. Presentation Topics

5. Recommended Frontline Therapies for FL

6. Considerations in Selecting Therapy for R/R FL

7. Recommended Second-Line Therapies for FL

8. Management Challenges in R/R FL

9. Strategies for Selecting Therapy for R/R FL

10. Novel Therapies

11. Copanlisib

12. CHRONOS-1 Trial of Copanlisib Methods

13. CHRONOS-1 Trial of Copanlisib Efficacy

14. CHRONOS-1 Trial of Copanlisib Safety

15. Idelalisib

16. Phase 2 Trial of Idelalisib Monotherapy in R/R FL Design and Efficacy

17. Phase 2 Trial of Idelalisib Monotherapy in R/R FL Safety

18. Duvelisib

19. DYNAMO Trial of Duvelisib

20. MAGNIFY Trial of Rituximab + Lenalidomide Design

21. MAGNIFY Trial Response

22. MAGNIFY Trial PFS

23. MAGNIFY Trial Safety

24. Additional Trials of R + Lenalidomide

25. Obinutuzumab

26. GADOLIN Trial Design

27. GADOLIN Trial Efficacy

28. GADOLIN Trial Safety

29. Incorporating New Agents Into Treatment Paradigm Challenges

30. Incorporating New Agents Into Treatment Paradigm Selection

31. Current Knowledge About Novel Agents

32. Ongoing Trials in R/R FL

33. Abbreviations

34. Abbreviations (cont)